As a regional referral centre and major teaching hospital, Lille University Hospital is providing the highest quality care for more than 4.2 million inhabitants with 1.4 million outpatients treated each year. With 16,000 professionals, it is one of the largest campuses in Northern Europe. Its integrated resources and expertise offer patients a sophisticated facility including state-of-the art medical equipment, providing comprehensive and specialized care from birth to geriatrics. Lille University Hospital is committed to excellence in medical research and innovative approaches, education and patient care.
The EPIMAD registry is part of Lille University Hospital. It is one of the largest population-based registries related to IBD in the world covering four departments in Northern France (Nord, Pas-de-Calais, Somme and Seine-Maritime) and includes three teams of researchers based at the academic hospitals Centre Hospitalier Universitaire, Pr Ley and Dr Sarter of Lille. In addition, EPIMAD is also located at Pr Fumery in Amiens and Pr Savoye in Rouen. The registry covers a large area of Northern France with almost six million inhabitants representing 9% of the entire French population. All the adult (n=250) and paediatric (n=12) gastroenterologists, regardless of their type of practice (hospital or private) have reported incident cases of IBD since 1988. In addition to gastroenterologists, the registry includes biostatisticians and interviewing practitioners who collect clinical data for each new case from medical records using a standardized questionnaire. To date, approximately 26,000 patients with IBD are registered in the database. The EPIMAD registry's primary mission is to provide information on the epidemiology and natural history of IBD in France. The registry's organization also allows for interventional studies, particularly on the identification of pathophysiological and environmental factors potentially involved in IBD.
Role within INTERCEPT
Coordinated by Centre Hospitalier Universitaire de Lille the three academic centres of the EPIMAD registry (Amiens, Lille, and Rouen), each following more than 1,500 patients with IBD, will participate in work package 3 of the INTERCEPT consortium - PREDICT-CD study (Prospective risk evaluation and detection of Crohn’s Disease in First-degree Relatives) - and work package WP4 - HALT-CD clinical trial. Also, the 262 gastroenterologists participating in the EPIMAD registry will be contacted in order to identify participants for the trials. In addition, the EPIMAD registry will be able to directly contact patients included in the registry, with the agreement of their gastroenterologist. This will also be done with the support of the national association of patients with IBD (AFA Crohn RCH France). Collection and storage will be organized at the biobank of the three centres (Amiens, Lille and Rouen) in order to promote proximity to the trial participants.
Main contacts
Dr, PhD Helene Sarter
Head of EPIMAD registry
Pr Delphine Ley
Head of EPIMAD Lille
Dr Pauline Wils
EPIMAD Lille
Dr, PhD Florence Nosal
European projects officer
Dr, PhD Françoise Leal
European projects officer